Back HCV Policy & Advocacy

HCV Policy & Advocacy

EASL 2016: How Generic Direct-Acting Antivirals Are Changing the Hepatitis C Treatment Landscape

The arrival of generic versions of direct-acting antivirals (DAAs) is transforming the global hepatitis C treatment landscape and highlighting the overlooked importance of the cost of monitoring technologies, presenters said at the EASL International Liver Congress (EASL 2016) last week in Barcelona.

alt

Read more:

EASL 2016: Low-Cost Generic Hepatitis C Drugs Match Branded Products in Viral Response

Generic versions of direct-acting antivirals for hepatitis C purchased from China and India by people unable to obtain treatment in their own countries were just as effective and safe as the branded products, a study of 139 patients monitored by Australian doctor James Freeman has shown. The findings were presented in a late-breaking research session at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) in Barcelona on Saturday.

alt

Read more:

FY 2017 Budget Sustains HIV Funding, Requests More for PrEP, Opioid Epidemic

President Barack Obama's proposed budget for fiscal year 2017 modestly increases funding for domestic HIV services -- with $20 million allocated for a pre-exposure prophylaxis (PrEP) pilot programand $9 million for HIV/HCV coinfection -- but flat funds HIV research and global AIDS assistance. The budget also address the growing opioid epidemic and includes efforts to expand Medicaid and reduce prescription drug costs.

alt

Read more:

EASL 2016: Liver Associations Worldwide Call for Elimination of Viral Hepatitis

Leaders of liver disease associations from Europe, the U.S., Latin America, and Asia released a Joint Society Statement on Elimination of Viral Hepatitis at the opening session of the International Liver Congress (EASL 2016) this week in Barcelona, calling for enhanced efforts to diagnose and treat hepatitis B and C, with the goal of eliminating viral hepatitis as a public health threat.

alt

Read more:

9. HIV and Hepatitis C Treatment Cost and Barriers to Access

Lack of access to HIV and hepatitis C treatment were key issues this year, as studies showed that type of health insurance affects the likelihood of successful treatment. HIV now has the potential to be a chronic manageable illness and hepatitis C can usually be cured, but major barriers and disparities continue to keep many people from accessing treatment.

alt

Read more: